Previous studies have reported that high levels of estrogen receptor (ER) accumulation in patients with non-small cell lung cancer (NSCLC) positively feedback to activate AKT, which ultimately suppresses the expression of PTEN, leading to cisplatin resistance in NSCLC (9). This evidence concerns the gene ESR1 and non-small cell lung carcinoma.